Trial Profile
A Multicenter, Open-Label, Phase 2 Study to Determine the Dose, Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Combination With Cetuximab in Patients With Solid Tumors Refractory to Standard Treatment and to Evaluate the Safety and Efficacy of NKTR-102 or Irinotecan in Combination With Cetuximab in Second Line, Irinotecan and Cetuximab Naïve, Colorectal Cancer Patients With Metastatic or Locally Advanced Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2021
Price :
$35
*
At a glance
- Drugs Etirinotecan pegol (Primary) ; Cetuximab
- Indications Colorectal cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Nektar Therapeutics
- 14 Aug 2014 According to ClinicalTrials.gov record, phase IIb part of the study was not conducted.
- 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jan 2009 Status changed from recruiting to active, no longer recruiting, according to Nektar therapeutics media release.